Renaissance Pharma (NASDAQ: RENA) Gains FDA Fast Track for Daretabart in Neuroblastoma
Key Developments Renaissance Pharma (NASDAQ: RENA), a company specializing in developing essential pharmaceutical assets, has received a significant milestone from the US Food and Drug Administration (FDA). The FDA granted Fast Track Designation to its investigational treatment Daretabart (hu1418K322A), aimed at treating high-risk neuroblastoma, a rare and aggressive pediatric cancer. This Fast Track status recognizes the urgent need for effective therapies in this patient population and will facilitate the development…
